Fig. 2 | Diabetologia

Fig. 2

From: Mesenchymal stromal cell-derived exosomes ameliorate peripheral neuropathy in a mouse model of diabetes

Fig. 2

 MSC-exosomes improve neurological outcomes. (a) Schematic representation showing the treatment regimen of mice. (b, c) Before treatment (week 0), both MCV (b) and SCV (c) in the diabetic group were significantly decreased compared with the non-diabetic group of the same age. However, 8 weeks of treatment with MSC-exosomes significantly improved both MCV and SCV. Threshold to mechanical stimuli (d) and thermal response latency (e) in diabetic mice were decreased after MSC-exosome treatment. Data are mean ± SEM and were analysed by a one-way ANOVA with Tukey’s post hoc test (n = 8/group). p < 0.05, ††p < 0.01, †††p < 0.001 db/db vs db/m; *p < 0.05, **p < 0.01 db/db vs db + exo. db/db, diabetic group treated with saline; db + exo, diabetic group treated with MSC-exosomes; db/m, non-diabetic group

Back to article page